With $29M in Se­ries A, Boehringer-backed Li­bra looks to tack­le neu­rode­gen­er­a­tion through cel­lu­lar clean­ing

Can the nat­ur­al process by which cells clean out tox­ic pro­teins be har­nessed to cre­ate po­ten­tial treat­ments for neu­rode­gen­er­a­tive dis­or­ders?

That’s the ques­tion Li­bra Ther­a­peu­tics will be try­ing to an­swer, as the new biotech of­fi­cial­ly launched Wednes­day morn­ing with $29 mil­lion in Se­ries A fi­nanc­ing. The com­pa­ny has three pre­clin­i­cal pro­grams at the ready, with its lead can­di­date tar­get­ing ALS and fron­totem­po­ral de­men­tia. But CEO Isaac Vein­bergs said he hopes to de­vel­op ther­a­pies for a wide range of dis­eases, in­clud­ing Parkin­son’s, Alzheimer’s and Hunt­ing­ton’s.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER